Zoetis Inc. continues to grapple with financial challenges, having reported disappointing Q1 2026 earnings with revenues of $2.26 billion, falling short of expectations by 5.3%. The company has revised its full-year guidance downward due to weaker demand in the companion animal sector and mounting competition, resulting in a 39% year-to-date stock decline. Although shares plummeted over 21% following these announcements, Zoetis is looking to bolster its portfolio through a forthcoming acquisition of Neogen’s animal genomics business in H2 2026.
Loading timeline…
